中药预知子乙醇提取物抗抑郁作用的实验研究

目的：N-究预知子乙醇提取物的抗抑郁作用,并初步探讨其作用机制。方法：采用小鼠悬尾实验、强迫游泳实验,抑制单胺重摄取作用实验等动物模型来考察预知子乙醇提取物抗抑郁作用及其作用机制。结果：预知子乙醇提取物能够显著缩短小鼠悬尾及强迫游泳不动时间;显著增加多巴胺（DA）致小鼠死亡作用和阿朴吗啡致小鼠刻板运动作用;增加5-羟色胺酸（5-HTP）致甩头作用,但对去甲肾上腺素（NE）重摄取抑制作用不明显。结论：预知子乙醇提取物有抗抑郁活性,与其增强5-HT、DA神经系统作用有关。     

积雪草总苷元抗抑郁作用的研究

目的探讨积雪草总苷元的抗抑郁作用及其可能作用机制。方法采用大鼠强迫游泳实验,抑制单胺重摄取作用实验等动物模型来考察积雪草总苷元抗抑郁作用及其可能作用机制。结果积雪草总苷元能够显著缩短大鼠游泳不动时间;对单胺类递质去甲肾上腺素 (NE)、多巴胺 (DA)重摄取抑制作用不明显,但是显著增加5-羟色氨酸致小鼠甩头作用。结论积雪草总苷元有抗抑郁活性,可能与其增加5-羟色胺（5-HT）能神经系统有关。     

柴胡皂苷对石菖蒲醇沉液抗抑郁作用的影响

目的观察石菖蒲醇沉液的抗抑郁作用及柴胡皂苷对其抗抑郁作用的影响。方法选用小鼠尾悬挂试验、大鼠强迫游泳试验和小鼠5-HTP增强试验分别测定小鼠悬尾不动时间、大鼠强迫游泳不动时间和小鼠甩头次数。结果在小鼠尾悬挂试验和大鼠强迫游泳试验中，石菖蒲醇沉液能使小鼠和大鼠的不动时间显著缩短，柴胡皂苷可加强石菖蒲醇沉液缩短小鼠、大鼠不动时间的作用；在小鼠5-HTP增强甩头试验中，较大剂量（10g／kg）的石菖蒲醇沉液能增强小鼠甩头反应，柴胡皂苷有加强石菖蒲醇沉液增强小鼠甩头反应的作用。结论石菖蒲醇沉液有抗抑郁作用，柴胡皂苷可加强石菖蒲醇沉液的抗抑郁作用。     

遍地金不同提取物的抗抑郁作用

目的筛选遍地金提取物的抗抑郁活性组分,并初步了解各活性组分的抗抑郁作用机制。方法将遍地金提取物分为3个不同的组分,应用6种抗抑郁药理模型筛选抗抑郁活性组分。结果提取物中所有组分的中、小剂量均可显著增加大鼠成功逃避次数,大剂量均可显著减少小鼠的游泳不动时间;水、正丁醇提取组分各个剂量均可显著减少小鼠的悬尾不动时间。但5-HTP致小鼠甩头行为实验中,各组分无显著性差异;利血平及阿朴吗啡引起的体温降低试验中,各组分也无显著性差异。结论遍地金的水、正丁醇提取组分均有较好的抗抑郁作用,水提取组分的效果最佳,正丁醇提取组分次之。     

绿萼梅总黄酮对小鼠抑郁的改善作用

目的研究绿萼梅总黄酮对小鼠的抗抑郁作用。方法采用昆明种小鼠随机分为对照组、阿米替林或氟西汀(20 mg/kg)组、绿萼梅总黄酮(120、240、360 mg/kg)组,每小组各12只,每天ig给药1次。通过小鼠强迫游泳实验、悬尾实验、利血平诱导眼睑下垂和体温降低模型、5-羟基色氨酸(5-HTP)诱导小鼠甩头模型,考察绿萼梅总黄酮的影响。结果绿萼梅总黄酮各剂量均能显著缩短小鼠强迫游泳、悬尾不动时间(P0.05、0.01);绿萼梅总黄酮240、360 mg/kg能显著抑制利血平诱导的小鼠眼睑下垂和体温降低(P0.05、0.01),同时能显著增强5-HTP诱导的小鼠甩头次数(P0.05、0.01)。结论绿萼梅总黄酮对小鼠各模型有抗抑郁的作用。     

棉籽总黄酮抗抑郁作用的研究

目的探讨棉籽总黄酮(代号:CTN-T)抗抑郁活性。方法采用小鼠悬尾模型、大小鼠强迫游泳模型、5-羟色氨酸(5-hydroxy-L-tryptophan,5-HTP)诱导小鼠甩头模型、小鼠育亨宾毒性增强模型探讨CTN-T的抗抑郁活性及其可能作用环节。结果小鼠悬尾实验中,CTN-T单次灌胃160~320mg.kg-1或连续4 d(每天2次)灌胃60 mg.kg-1缩短悬尾不动时间;在小鼠强迫游泳实验中,CTN-T连续7 d灌胃给药(每天2次)在40~60 mg.kg-1缩短游泳不动时间;在大鼠强迫游泳实验中,CTN-T连续4 d灌胃(每天2次)20~60mg.kg-1缩短游泳不动时间;此外,小鼠单次灌胃CTN-T160 mg.kg-1或连续4 d(每天2次)灌胃80 mg.kg-1增强5-HTP诱导的甩头行为。而小鼠连续4 d灌胃CTN-T 60~180 mg.kg-1对育亨宾毒性均无影响。结论CTN-T有抗抑郁活性,可能与其增强脑内5-HT神经功能有关。     

新型5-HT1A受体激动和5-HT重摄取抑制双重活性化合物YL-0919抗抑郁作用的行为学评价

目的研究兼有5-HT1A受体激动和5-HT重摄取抑制双重活性化合物YL-0919的抗抑郁作用。方法分别采用小鼠悬尾实验、小鼠强迫游泳实验、小鼠自发活动实验和大鼠获得性无助模型,观察不同剂量（0.625、1.25、2.5和5mg/kg）YL-0919的抗抑郁作用。结果在小鼠悬尾实验和小鼠强迫游泳实验中,单次灌胃给予YL-0919（0.625～2.5mg/kg）能够显著缩短小鼠悬尾不动时间和游泳不动时间;在小鼠自发活动实验中,YL-0919在上述剂量范围对自发活动无影响;在大鼠获得性无助模型上,灌胃给予YL-0919〔0.625～1.25mg/（kg·d）,1~4d〕能显著减少逃避失败次数。结论 YL-0919在小鼠和大鼠模型上具有明确的抗抑郁活性,并且在抗抑郁的有效剂量范围内无中枢兴奋和抑制作用,具有成为新型抗抑郁药物的研发潜力。     

姜黄素二癸酸酯的制备及长效性研究

制备姜黄素二癸酸酯,并对其药理长效性进行研究。姜黄素与癸酰氯发生酯化后形成姜黄素二癸酸酯(Curcumin didecanoate,CDD),将CDD或姜黄素注射到小鼠和大鼠体内,测定小鼠和大鼠血浆中姜黄素含量,检测时量效应;利用5-HTP诱导甩头实验,检测CDD的抗抑郁作用的长效性。结果显示一次性注射CDD(184 mg/kg),小鼠及大鼠的姜黄素有效血药浓度可以持续至少14 d。与姜黄素相比,CDD具有明显的长效特点;5-HTP诱导甩头实验,显示其具有抗抑郁作用。     

四神丸抗抑郁作用及其对中枢单胺神经系统的影响

目的 评价四神丸的抗抑郁作用并探究其可能机制。方法成年雄性ICR小鼠慢性给予四神丸(1.25,2.5和5 g·kg^-1,ig),采用强迫游泳和悬尾实验评价四神丸的抗抑郁作用;采用旷场实验评价其对中枢神经系统兴奋性的影响;采用5-羟色氨酸(5-HTP)诱发甩头实验和育亨宾毒性增强实验评价四神丸对5-羟色胺(5-HT)能和去甲肾上腺素能神经系统的影响;在脂多糖(LPS,1 mg·kg^-1,ip)诱导小鼠抑郁模型上,采用悬尾实验和蔗糖偏嗜实验评价四神丸(1.25,2.5和5 g·kg^-1,ig给药30 d)的抗抑郁作用;采用高效液相色谱法(HPLC)检测LPS模型小鼠海马单胺递质5-HT和多巴胺(DA)及其代谢物的水平。结果 与正常对照组相比,四神丸1.25和5 g·kg^-1慢性给药显著降低小鼠强迫游泳和悬尾的不动时间(P<0.05);对旷场实验的运动总距离和运动时间无明显影响;在5-HTP诱导甩头实验中,四神丸5 g·kg^-1慢性给药显著增加小鼠甩头次数(P<0.01)...     

中药SXY-006的抗抑郁作用研究

目的：研究中药SXY-006的抗抑郁作用。方法：采用小鼠悬尾实验、小鼠强迫游泳实验、大鼠单次及多次给药后强迫游泳实验、5一羟色胺酸（5．HTP）诱导的小鼠甩头实验、利血平引起的小鼠睁眼不能以及运动不能实验、大鼠慢性不可预知性抑郁症造模后的敞箱（open—field）实验，评价SXY-006的抗抑郁作用。结果：SXY-006中（100mg&#183;1000g-1）、高（300mg&#183;1000g-1）剂量均能明显减少小鼠悬尾实验和强迫游泳实验的不动时间（P〈0．01），SXY-006低（25mg&#183;1000g-1）、中（100mg&#183;1000g-1）、高（300mg&#183;1000g-1）剂量均能减少大鼠单次和多次给药后强迫游泳实验的不动时间（P〈0．01—0．05），均能显著增加5-HTP诱导的甩头实验的小鼠甩头次数（P〈0．01）。均能明显拮抗利血平引起的小鼠的睁眼不能和运动不能（P〈0．01），均能增加大鼠慢性不可预知性抑郁症造模后大鼠的水平得分（P〈0．05），明显增加其垂直得分（P〈0．01）。结论：中药SXY-006具有抗抑郁的作用。     

积雪草总三萜酸及其主要成分的抗抑郁活性研究

目的:探讨积雪草总三萜酸和其主要成分积雪草酸、羟基积雪草酸的抗抑郁作用.方法:采用小鼠强迫游泳实验、小鼠悬尾实验、开野实验和拮抗利血平所致的小鼠眼睑下垂实验,分别以小鼠不动时间、自主活动数和拮抗率作为评价指标.结果:在强迫游泳实验中积雪草总三萜酸、积雪草酸、羟基积雪草酸60 mg/kg、120 mg/kg剂量均能显著缩短小鼠不动时间,在悬尾实验中30 mg/kg、60 mg/kg、120 mg/kg剂量均能显著缩短小鼠不动时间,开野实验结果表明给药后小鼠的自主活动无明显变化,在利血平拮抗实验中积雪草总三萜酸、积雪草酸、羟基积雪草酸均可减少小鼠眼睑下垂.结论:积雪草总三萜酸、积雪草酸、羟基积雪草酸有抗抑郁作用.     

N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice

The antidepressant-like effects of N-palmitoylethanolamide (PEA), a putative endocannabinoid, was investigated in mice using the tail suspension test (TST) and the forced swimming test (FST). In TST, PEA (10, 20, and 40 mg/kg) produced a statistically significant reduction in immobility (50, 32, and 34%, respectively, vs. the control group), whereas fluoxetine (20 mg/kg) reduced immobility by 38%. In FST, PEA (5, 10, and 20 mg/kg) produced a statistically significant reduction in immobility (15, 21, and 36%, respectively), whereas fluoxetine (20 mg/kg) reduced immobility by 18%. Moreover, PEA (20 mg/kg) did not significantly change motor activity in a spontaneous behavioral test. In conclusion, PEA (dose range of 5-40 mg/kg) administered orally reduced immobility in TST and FST, comparable to the antidepressant effect of fluoxetine, and had no effect on spontaneous activity in mice.     

Antidepressant-like effects of piperine and its derivative,antiepilepsirine

In the present study, antidepressant-like effects of piperine (PIP) and its derivative, antiepilepsirine (AES), were investigated in two depressive models: forced swimming test (FST) and tail suspension test (TST). To further explore the mechanisms underlying their antidepressant-like activities, the brain monoamine levels and monoamine oxidase A and B (MAO-A and MAO-B) activities were also determined. The research results for the first time indicated that after two weeks of chronic administration, PIP and AES at doses of 10–20 mg/kg significantly reduced the duration of immobility in both FST and TST, without accompanying changes in locomotor activity in the open-field test. But at the dose of 80 mg/kg, the antidepressant activity of both PIP and AES returned to the control level in the TST and FST. In the monoamine assay, chronic AES administration significantly elevated the dopamine level in striatum, hypothalamus and hippocampus, and also increased the serotonin level in the hypothalamus and hippocampus. In contrast, chronic treatment of PIP only enhanced the serotonin level in the hypothalamus and hippocampus but did not influence the dopamine level. Moreover, both PIP and AES showed no effects on level of noradrenaline in these brain regions. The MAO activity assay also indicated that PIP and AES showed a minor MAO inhibitory activity. In the present study, we demonstrated that the antidepressant-like effects of PIP and AES might depend on the augmentation of the neurotransmitter synthesis or the reduction of the neurotransmitter reuptake. Antidepressant properties of PIP were supposed to be mediated via the regulation of serotonergic system, whereas the mechanisms of antidepressant action of AES might be due to its dual regulation of both serotonergic and dopaminergic systems.     

Antidepressant-like effects of piperine and its derivative, antiepilepsirine

In the present study, antidepressant-like effects of piperine (PIP) and its derivative, antiepilepsirine (AES), were investigated in two depressive models: forced swimming test (FST) and tail suspension test (TST). To further explore the mechanisms underlying their antidepressant-like activities, the brain monoamine levels and monoamine oxidase A and B (MAO-A and MAO-B) activities were also determined. The research results for the first time indicated that after two weeks of chronic administration, PIP and AES at doses of 10-20 mg/kg significantly reduced the duration of immobility in both FST and TST, without accompanying changes in locomotor activity in the open-field test. But at the dose of 80 mg/kg, the antidepressant activity of both PIP and AES returned to the control level in the TST and FST. In the monoamine assay, chronic AES administration significantly elevated the dopamine level in striatum, hypothalamus and hippocampus, and also increased the serotonin level in the hypothalamus and hippocampus. In contrast, chronic treatment of PIP only enhanced the serotonin level in the hypothalamus and hippocampus but did not influence the dopamine level. Moreover, both PIP and AES showed no effects on level of noradrenaline in these brain regions. The MAO activity assay also indicated that PIP and AES showed a minor MAO inhibitory activity. In the present study, we demonstrated that the antidepressant-like effects of PIP and AES might depend on the augmentation of the neurotransmitter synthesis or the reduction of the neurotransmitter reuptake. Antidepressant properties of PIP were supposed to be mediated via the regulation of serotonergic system, whereas the mechanisms of antidepressant action of AES might be due to its dual regulation of both serotonergic and dopaminergic systems.     

3，6＇-二芥子酰基蔗糖抗抑郁作用及对新生大鼠海马神经前体细胞增殖的影响

目的探讨远志活性成分3,6’-二芥子酰基蔗糖（DISS）的抗抑郁作用及对新生大鼠海马神经前体细胞增殖的影响。方法通过小鼠悬尾和强迫游泳试验来考察DISS抗抑郁作用;体外分离培养新生大鼠海马神经前体细胞,同时给予DISS,用四甲基噻唑蓝（MTT）法测定细胞存活率,观察DISS对神经细胞增殖的影响,并初步探讨其抗抑郁的作用机制。结果DISS不同剂量（5,10,20mg／kg）给药后,能明显缩短小鼠在悬尾和强迫游泳试验中的不动时间,并且随着剂量的增大抗抑郁作用逐渐降低;DISS不同质量浓度（0．4,10,50~g／mL）对所培养具神经前体细胞特性的细胞有促进增殖的作用。结论DISS具有较好的抗抑郁作用,该作用可能是通过调控神经干细胞的增殖、促进功能性神经再生和保护作用实现的。     

Antidepressant-like effects of piperine and its derivative, antiepilepsirine

In the present study, antidepressant-like effects of piperine (PIP) and its derivative, antiepilepsirine (AES), were investigated in two depressive models: forced swimming test (FST) and tail suspension test (TST). To further explore the mechanisms underlying their antidepressant-like activities, the brain monoamine levels and monoamine oxidase A and B (MAO-A and MAO-B) activities were also determined. The research results for the first time indicated that after two weeks of chronic administration, PIP and AES at doses of 10-20 mg/kg significantly reduced the duration of immobility in both FST and TST, without accompanying changes in locomotor activity in the open-field test. But at the dose of 80 mg/kg, the antidepressant activity of both PIP and AES returned to the control level in the TST and FST. In the monoamine assay, chronic AES administration significantly elevated the dopamine level in striatum, hypothalamus and hippocampus, and also increased the serotonin level in the hypothalamus and hippocampus. In contrast, chronic treatment of PIP only enhanced the serotonin level in the hypothalamus and hippocampus but did not influence the dopamine level. Moreover, both PIP and AES showed no effects on level of noradrenaline in these brain regions. The MAO activity assay also indicated that PIP and AES showed a minor MAO inhibitory activity. In the present study, we demonstrated that the antidepressant-like effects of PIP and AES might depend on the augmentation of the neurotransmitter synthesis or the reduction of the neurotransmitter reuptake. Antidepressant properties of PIP were supposed to be mediated via the regulation of serotonergic system, whereas the mechanisms of antidepressant action of AES might be due to its dual regulation of both serotonergic and dopaminergic systems.     

知母皂苷B-Ⅱ纳米纤维膜制备及体外抗肿瘤活性的初步研究

目的探索知母皂苷B-Ⅱ纳米纤维膜的制备方法,为后续进行体内相关研究打好基础.方法：将知母皂苷B-Ⅱ与聚乳酸（PLLA）按照不同比例制成知母皂苷B-Ⅱ纳米纤维膜;分别采用扫描电镜、红外光谱分析、LC-MS/MS 检测方法对纤维膜理化性质表征、生物相容性、缓释性能等进行测试;采用CCK-8法检测载药纳米膜缓释药物抑制胃癌细胞的增殖情况.结果：12%的知母皂苷B-Ⅱ浓度为最佳载药浓度;在制备载知母皂苷B-Ⅱ纳米纤维的过程中,静电纺丝技术能保持两种组分各自的化学特征及物理性质;知母皂苷B-Ⅱ对纤维膜的热稳定性影响不大,两者相容性较好;知母皂苷B-Ⅱ纳米纤维膜可有效释放知母皂苷B-Ⅱ,明显抑制BGC-823细胞的增殖活性,在48 h、72 h 与对照组细胞相比较,差异具有统计学意义（P 〈0.05）.结论：知母皂苷B-Ⅱ纳米纤维膜通过缓释药物可有效抑制BGC-823细胞的增殖能力.     

槟榔壳总酚类提取物抗抑郁作用研究

目的:探讨槟榔壳总酚类提取物对抑郁模型小鼠的抗抑郁作用。方法:采用小鼠悬尾、强迫游泳等抑郁模型,以小鼠行为绝望的不动时间作为指标,考察槟榔壳总酚类抗抑郁活性。结果:槟榔壳总酚类320,160 mg.kg-1剂量组均能显著减少小鼠悬尾和强迫游泳的不动时间。结论:槟榔壳总酚类可以改善小鼠的绝望行为,具有明显的抗抑郁作用。     

柴芪口服液抗抑郁作用实验研究

摘要目的：实验观察柴芪口服液的抗抑郁作用。方法：将动物随机分为空白对照组、阳性对照（氟西汀）组、柴芪口服液高、中、低剂量组,分别灌胃给予同等容积的相应药物,qd,连续给予14d,末次给药后40min,采用小鼠悬尾实验、强迫游泳实验及开场实验等方法观察柴芪口服液的抗抑郁作用。结果：在小鼠强迫游泳实验和小鼠悬尾实验中,柴芪口服液大剂量（生药6．4g·kg^-1）能明显缩短两种“行为绝望”模型小鼠的不动时间;在小鼠开场实验中,柴芪口服液6．4g·kg^-1使小鼠水平方向活动次数显著提高,与对照组比较有显著性差异（P＜0．05）。结论：柴芪口服液具有抗抑郁作用。     

Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems

Clinical studies have shown that folic acid plays a role in the pathophysiology of depression. However, very few studies have investigated its effect in behavioral models of depression. Hence, this study tested its effect in the forced swimming test (FST) and the tail suspension test (TST), two models predictive of antidepressant activity, in mice. Folic acid administered by oral route (p.o.) produced a reduction in the immobility time in the FST (50-100mg/kg) and in the TST (10-50mg/kg). The administration of folic acid by i.c.v. route also reduced the immobility time in the FST (10nmol/site) and in the TST (1-10nmol/site). Both folic acid administered by oral and i.c.v. route produced no psychostimulant effect, which indicates that its antidepressant-like effect is specific. Pretreatment of mice with p-chlorophenylalanine methyl ester (PCPA; 100mg/kg, i.p., an inhibitor of serotonin (5-HT) synthesis, for 4 consecutive days), ketanserin (5mg/kg, i.p., a 5-HT(2A/2C) receptor antagonist), prazosin (1mg/kg, i.p., an alpha(1)-adrenoceptor antagonist) or yohimbine (1mg/kg, i.p., an alpha(2)-adrenoceptor antagonist) prevented the anti-immobility effect of folic acid (50mg/kg, p.o.) in the FST. Moreover, the pretreatment of mice with WAY100635 (0.1mg/kg, s.c., a selective 5-HT(1A) receptor antagonist) blocked the decrease in immobility time in the FST elicited by folic acid (50mg/kg, p.o.), but produced a synergistic effect with a subeffective dose of folic acid (10mg/kg, p.o.). In addition, a subeffective dose of folic acid (10mg/kg, p.o.) produced a synergistic antidepressant-like effect with fluoxetine (10mg/kg, p.o.) in the FST. Overall, the results firstly indicate that folic acid produced an antidepressant-like effect in FST and in TST and that this effect appears to be mediated by an interaction with the serotonergic (5-HT(1A) and 5-HT(2A/2C) receptors) and noradrenergic (alpha(1)- and alpha(2)-adrenoceptors) systems.